Ifm_05-may 2022 Direct

Early versus Late Discontinuation of Maintenance Therapy in ... - MDPI

One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations

Patients are encouraged to discuss the balance between disease control and the toxic long-term effects of maintenance drugs with their oncology team. IFM_05-May 2022

Lenalidomide was the primary drug used for maintenance in this study. Key Findings:

The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment. Early versus Late Discontinuation of Maintenance Therapy in

Research published around May 2022 explored the impact of "early" vs. "late" discontinuation (stopping before or after 3 years), noting that early stopping is often forced by toxicity rather than choice.

If you are looking for guidance based on this study's results: Lenalidomide was the primary drug used for maintenance

Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen.